Can new staging tools better track ALS progression?

NCT ID NCT04858555

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at two new ways to stage amyotrophic lateral sclerosis (ALS) based on key disease milestones. Researchers will check how well these systems work in 50 patients and see if adding a blood marker called neurofilament can improve tracking of the disease. The goal is to better understand ALS progression, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a more accurate way to stage ALS, helping doctors better understand and track the disease.

What could go wrong

This is a small, observational study with only 50 patients from one center, so results may not apply to everyone. It is not testing a treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Limoges University Hospital

    Limoges, 87042, France

  • Tours University Hospital

    Tours, 37044, France